Clinical Trial

Efficacy of Injectable Gentamicin in Hereditary Ichthyosis

Study acronym: GENTIC
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 5, 2024 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the efficacy and safety of intravenous gentamicin in congenital ichthyosis due to a non-sens mutation. The primary objective is the severity of scales and erythema at the third month, compared to baseline. Secondary objectives will include: the importance of itching, trans epidermal water loss, cutaneous expression of the targeted protein, the security of the drug and patients' satisfaction.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-08.
Trial Details
NCT Number NCT06362447
Lead Sponsor University Hospital, Toulouse
Conditions Ichthyosis
Enrollment 26 participants
Start Date 2024-09
Primary Completion 2026-04-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-09-05